Search Results - jun+wang

17 Results Sort By:
Telaprevir-derived Enterovirus D68 2A protease inhibitors are antiviral drug candidates
Published data for lead compounds, the telaprevir-derived 2Apro inhibitor Jun11762 and others, demonstrate substantial improvement over Telaprevir in plaque assay. See link to paper below. ​ Invention Summary: The genus Enterovirus of Picornaviridae contains many significant pathogens related to human and mammalian diseases. Enterovirus D68...
Published: 7/31/2025   |   Inventor(s): Jun Wang, Bin Tan, Prakash Jadhav, Kan Li
Keywords(s): Antiviral, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Fumaramide SARS-CoV-2 papain-like protease inhibitors are antiviral drug candidates
​ Published data for lead compound, the fumaramide PLpro inhibitor Jun13728, demonstrate potent inhibition of SARS-CoV2 variants including nirmatrelvir-resistant mutant (light blue). Link to paper below. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for...
Published: 7/31/2025   |   Inventor(s): Jun Wang, Bin Tan, Prakash Jadhav, Ahmadullah Ansari, Francesc Ruiz Figueras, Edward Arnold
Keywords(s):  
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Quinoline-derived SARS-CoV-2 papain-like protease inhibitors are oral antiviral drug candidates
​ A lead compound, the quinoline-derived PLpro inhibitor Jun13296, demonstrates substantial protection against SARS-CoV-2 infection and adverse clinical outcomes. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for research to support pandemic preparedness...
Published: 7/31/2025   |   Inventor(s): Jun Wang, Prakash Jadhav, Bin Tan, Haozhou Tan
Keywords(s): Antiviral
Category(s): Technology Classifications > COVID-19, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Enterovirus D68 capsid inhibitors as antivirals
​ Plaque assay results of Jun11-46-1 and Jun11-54-1 against EV-D68 US/MO/14-18947. Invention Summary: Enterovirus D68 (EV-D68) is an RNA virus that mainly affects children and results in moderate to severe respiratory illness, with the most extreme cases resulting in muscle weakness, paralysis, and death. Currently, there are no antivirals...
Published: 1/27/2025   |   Inventor(s): Jun Wang, Yanmei Hu, Kan Li
Keywords(s): Antibacterial, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
Wearable tongue tracker for silent speech interfaces
MagTrack is a lightweight, wearable device that utilizes magnetic fields to track tongue movements, enabling silent speech recognition and other applications like speech therapy. Background Silent speech interfaces (SSIs) aim to restore communication for individuals who have lost their voice but retain the ability to articulate, such as those who...
Published: 10/23/2024   |   Inventor(s): Jun Wang, Beiming Cao
Keywords(s):  
Category(s): Life sciences > Diagnostic, Life sciences > Imaging
SARS-COV-2 papain-like protease inhibitors as antivirals
Novel compounds and their use as an inhibitor for SARS-CoV-2. Invention Summary: Two oral SARS-CoV-2 antivirals are available, molnupiravir and Paxlovid. However, the limited efficacy, drug-drug interaction, and drug resistance are main challenges facing these two drugs. Additional oral antivirals with novel mechanisms of actions are clearly needed....
Published: 7/9/2025   |   Inventor(s): Jun Wang, Edward Arnold, Francesc Ruiz Figueras, Prakash Jadhav, Bin Tan, Ahmadullah Ansari, Ashima Chopra
Keywords(s): Antiviral, Small molecules
Category(s): Technology Classifications > COVID-19, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences
Novel Main Protease Inhibitors as SARS-CoV-2 Antivirals
This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are potent main protease inhibitors with high...
Published: 2/2/2024   |   Inventor(s): Jun Wang
Keywords(s):  
Category(s): Technology Classifications > Life Sciences
A Novel Pan-T-Type Calcium Channel Modulator that alleviates Tonic, Neuropathic and Inflammatory Pain
This invention describes a non-opioid method to treat pain using a novel T-type calcium channel blocker. Background: Current treatments for many types of pain typically include opioid painkillers, which pose a significant risk of addiction and overdose in patients, creating a demand for a treatment with less risk and less side-effects. In neuropathic,...
Published: 11/16/2023   |   Inventor(s): Rajesh Khanna, Jun Wang
Keywords(s):  
Category(s): Technology Classifications, Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Small Molecules
Discovery of Pyrazolopyridine Analogs as Broad-Spectrum Antivirals against Non-Polio Enteroviruses including EV-D68, EV­A71, and CVB3
This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EV­A71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some...
Published: 1/10/2024   |   Inventor(s): Jun Wang, Naoya Kitamura
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Infectious Diseases
PLpro Inhibitors Against SARS-CoV-2
There are two cysteine proteases that are encoded by SARS-CoV-2, the main protease (Mpro) and the papain-like protease (PLpro). Both of these proteases have been shown to be essential in viral replication and are validated antiviral drug targets. PLpro cleaves the viral SARS-CoV-2 polyprotein at three sites. In addition, it modulates host immune response...
Published: 7/26/2024   |   Inventor(s): Jun Wang, Chunlong Ma, Naoya Kitamura, Yanmei Hu
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules
1 2